Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Collecting and storing stem cells to study in the laboratory may help doctors learn more about collecting stem cells from patients who have undergone treatment for Waldenstrom's macroglobulinemia.

PURPOSE: This laboratory study is collecting stem cells from patients with Waldenstrom's macroglobulinemia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Harvest and store adequate CD34+ stem cells from patients with Waldenstrom's macroglobulinemia (WM) for potential future use in transplantation strategies.
* Evaluate the ability to harvest stem cells after therapy for WM (e.g., fludarabine-based chemotherapy) by evaluating the number of days to adequate harvest.
* Collect aliquots of stem cells for future research analysis as part of a WM database project.

OUTLINE: Patients undergo collection of autologous stem cells beginning on day 4 or 5 and continuing until an adequate number of stem cells are collected. Cells are then cryopreserved.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Waldenström macroglobulinemia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

leukapheresis

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosis of Waldenstrom's macroglobulinemia (WM)
* Less than 30% lymphoplasmacytoid cells in bone marrow by histopathology
* Received prior chemotherapy for WM

PATIENT CHARACTERISTICS:

* ECOG performance status 0-1
* WBC \> 2,000/mm³
* Platelet count \> 50,000/mm³
* LVEF ≥ 50%
* No organ dysfunction that would preclude future transplantation

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gwen L. Nichols, MD

Role: STUDY_CHAIR

Herbert Irving Comprehensive Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center

New York, New York, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Clinical Trials Office - Herbert Irving Comprehensive Cancer C

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CPMC-AAAB4806

Identifier Type: -

Identifier Source: secondary_id

CDR0000487602